Endocrine changes in Alzheimer's disease

M. Davidson, L. Bastiaens, B. M. Davis, M. B. Shah, K. L. Davis

Research output: Contribution to journalReview articlepeer-review


At present, no consistent endocrine abnormalities can be detected in patients suffering from Alzheimer's disease. However, assessment of neuroendocrine function might help identify subpopulations of patients with particular neurotransmission abnormalities who are likely to benefit from a specific pharmacologic strategy. For example, patients in whom cholinomimetic drugs produce the greatest elevation in plasma cortisol concentration appear to derive the most symptomatic benefit from these drugs.

Original languageEnglish
Pages (from-to)149-157
Number of pages9
JournalEndocrinology and Metabolism Clinics of North America
Issue number1
StatePublished - 1988
Externally publishedYes


Dive into the research topics of 'Endocrine changes in Alzheimer's disease'. Together they form a unique fingerprint.

Cite this